1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. News
  7. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
End-of-day quote Korea Stock Exchange  -  05-23
808000.00 KRW   -1.34%
05/23SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
05/16South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies; SK Hynix Loses 2%
MT
05/16Samsung Biologics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Samsung Biologics' Q4 Net Profit Slumps, Revenue Jumps

01/25/2022 | 05:42am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
KOSPI COMPOSITE INDEX -1.26% 2610.67 Real-time Quote.-12.29%
SAMSUNG BIOLOGICS CO.,LTD. -1.34% 808000 End-of-day quote.-10.52%
SAMSUNG ELECTRONICS CO., LTD. -2.06% 66500 End-of-day quote.-15.07%
All news about SAMSUNG BIOLOGICS CO.,LTD.
05/23SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
05/16South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies..
MT
05/16Samsung Biologics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 3..
CI
04/29SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
04/28South Korea’s Kospi Adds 1% on Stellar Q1 Earnings; Samsung Biologics Adds 3%
MT
04/28Samsung Biologics' Net Income Surges 141% in March Quarter
MT
04/28Samsung Biologics Completes Full Acquisition Of Samsung Bioepis
AQ
04/27SAMSUNG BIOLOGICS : Material Business Matters Related to Investment Decisions
PU
04/21SAMSUNG BIOLOGICS : Results of issuance (Voluntary Disclosure)
PU
04/05Allakos Inc. Enters into A Master Development Services Agreement with Samsung Biologics..
CI
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Financials
Sales 2022 1 991 B 1,58 B 1,58 B
Net income 2022 542 B 0,43 B 0,43 B
Net Debt 2022 566 B 0,45 B 0,45 B
P/E ratio 2022 102x
Yield 2022 -
Capitalization 57 509 B 45 499 M 45 499 M
EV / Sales 2022 29,2x
EV / Sales 2023 25,6x
Nbr of Employees 2 886
Free-Float 25,6%
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 808 000,00
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Doyoung Heo Head-Finance & Vice President
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Sector and Competitors
1st jan.Capi. (M$)
SAMSUNG BIOLOGICS CO.,LTD.-10.52%46 268
CSL LIMITED-6.04%93 536
WUXI BIOLOGICS (CAYMAN) INC.-39.22%30 229
BIOGEN INC.-16.89%29 203
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-28.41%22 798
UCB-17.29%16 779